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Abstract
Background
The continued advance of antibiotic resistance threatens the treatment and control of many
infectious diseases. This is exemplified by the largest global outbreak of extensively drug-
resistant (XDR) tuberculosis (TB) identified in Tugela Ferry, KwaZulu-Natal, South Africa, in
2005 that continues today. It is unclear whether the emergence of XDR-TB in KwaZulu-
Natal was due to recent inadequacies in TB control in conjunction with HIV or other factors.
Understanding the origins of drug resistance in this fatal outbreak of XDR will inform the
control and prevention of drug-resistant TB in other settings. In this study, we used whole
genome sequencing and dating analysis to determine if XDR-TB had emerged recently or
had ancient antecedents.
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Methods and Findings
We performed whole genome sequencing and drug susceptibility testing on 337 clinical iso-
lates ofMycobacterium tuberculosis collected in KwaZulu-Natal from 2008 to 2013, in addi-
tion to three historical isolates, collected from patients in the same province and including
an isolate from the 2005 Tugela Ferry XDR outbreak, a multidrug-resistant (MDR) isolate
from 1994, and a pansusceptible isolate from 1995. We utilized an array of whole genome
comparative techniques to assess the relatedness among strains, to establish the order of
acquisition of drug resistance mutations, including the timing of acquisitions leading to
XDR-TB in the LAM4 spoligotype, and to calculate the number of independent evolutionary
emergences of MDR and XDR. Our sequencing and analysis revealed a 50-member clone
of XDRM. tuberculosis that was highly related to the Tugela Ferry XDR outbreak strain. We
estimated that mutations conferring isoniazid and streptomycin resistance in this clone
were acquired 50 y prior to the Tugela Ferry outbreak (katG S315T [isoniazid]; gidB 130 bp
deletion [streptomycin]; 1957 [95% highest posterior density (HPD): 1937–1971]), with the
subsequent emergence of MDR and XDR occurring 20 y (rpoB L452P [rifampicin]; pncA 1
bp insertion [pyrazinamide]; 1984 [95% HPD: 1974–1992]) and 10 y (rpoB D435G [rifampi-
cin]; rrs 1400 [kanamycin]; gyrA A90V [ofloxacin]; 1995 [95% HPD: 1988–1999]) prior to the
outbreak, respectively. We observed frequent de novo evolution of MDR and XDR, with 56
and nine independent evolutionary events, respectively. Isoniazid resistance evolved
before rifampicin resistance 46 times, whereas rifampicin resistance evolved prior to isonia-
zid only twice. We identified additional putative compensatory mutations to rifampicin in this
dataset. One major limitation of this study is that the conclusions with respect to ordering
and timing of acquisition of mutations may not represent universal patterns of drug resis-
tance emergence in other areas of the globe.
Conclusions
In the first whole genome-based analysis of the emergence of drug resistance among clini-
cal isolates ofM. tuberculosis, we show that the ancestral precursor of the LAM4 XDR out-
break strain in Tugela Ferry gained mutations to first-line drugs at the beginning of the
antibiotic era. Subsequent accumulation of stepwise resistance mutations, occurring over
decades and prior to the explosion of HIV in this region, yielded MDR and XDR, permitting
the emergence of compensatory mutations. Our results suggest that drug-resistant strains
circulating today reflect not only vulnerabilities of current TB control efforts but also those
that date back 50 y. In drug-resistant TB, isoniazid resistance was overwhelmingly the initial
resistance mutation to be acquired, which would not be detected by current rapid molecular
diagnostics employed in South Africa that assess only rifampicin resistance.
Introduction
The global burden of tuberculosis (TB) remains high, with an estimated 9 million active disease
cases and 1.5 million deaths in 2013 [1]. Multidrug-resistant (MDR) TB, defined asMycobacte-
rium tuberculosis with in vitro resistance to both isoniazid and rifampicin, accounted for at
least 480,000 incident cases and 210,000 attributed deaths in 2013 [1]. Extensively drug-
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resistant (XDR) TB, which is MDR with additional resistance to both quinolones and second-
line injectable agents [2], has been reported in 100 countries [1]. With high morbidity, XDR
poses a dire threat to public health, particularly in populations with high HIV prevalence [1,3].
The incidence of TB in South Africa is estimated by the WHO to be 860 (776–980) per
100,000 population, which is among the highest in the world [1]. With a population of approxi-
mately 10 million, KwaZulu-Natal is the easternmost of South Africa’s nine provinces. While
its provincial TB incidence is similar to that of the rest of South Africa (889 per 100,000 in
2012, based on treatment initiation data) [4], KwaZulu-Natal has been notable for dispropor-
tionately high rates of drug-resistant TB [4,5]. Compounding this epidemic, South Africa has
seen a dramatic increase in HIV prevalence in the last 25 y. The Joint United Nations Pro-
gramme on HIV and AIDS (UNAIDS) estimates that national adult HIV prevalence was only
0.3% in 1990 but rose to 19.1% in 2013 [6]. In KwaZulu-Natal, HIV rates are particularly high,
with 37.4% HIV prevalence documented among pregnant women in 2011 [4].
In 2005, the identification of an outbreak of XDR-TB at the Church of Scotland Hospital in
KwaZulu-Natal, Tugela Ferry, raised global alarm and called attention to the prospect of dis-
semination of potentially untreatable TB [7]. Not only was resistance to four or more classes of
antibiotics noted in these strains, but also the disease, in the context of HIV coinfection, was
rapidly fatal, with 98% mortality [7]. Traditional genotyping by IS6110 fingerprinting and spo-
ligotyping identified a predominant strain of globalM. tuberculosis lineage 4 and spoligotype,
ST60, later termed LAM4/F15/KZN (henceforth referred to as LAM4), suggestive of a clonal
outbreak of a single drug-resistant strain [7–11]. Targeted sequencing of resistance mutations
in a subset of these XDR strains revealed identical mutations [9], further supporting the theory
of acquisition of XDR-level resistance and subsequent transmission. Nosocomial spread was
deemed likely by a social network analysis [9].
Since the events at Church of Scotland Hospital, which still stands as the largest outbreak of
XDR-TB ever reported, XDR-TB has been reported in the majority of hospitals across Kwa-
Zulu-Natal [12], and more than 516 XDR-TB cases have been reported within Tugela Ferry
alone [13]. In addition, XDR-TB caused by strains not falling within the LAM4 spoligotype
have been seen, indicating repeated evolutionary emergences of XDR among strains circulating
within the region [10,14]; however, the relative contribution of de novo versus vertically inher-
ited resistance of XDR-TB is unknown. It is also unknown how and when XDR-level drug
resistance developed, information that could be exploited to detect and prevent higher-level
resistances from emerging in South Africa and elsewhere in the world.
While accumulation of drug-resistance mutations can confer a fitness cost to bacteria, sub-
sequent development of compensatory mutations can ameliorate these costs by restoring cer-
tain affected physiological functions while maintaining drug resistance [15–17]. Identification
of compensatory mutations among clinical strains ofM. tuberculosis [18–20] has improved our
understanding of drug resistance and fitness, but this area remains incompletely studied.
Whole genome sequencing efforts that target large collections ofM. tuberculosis have pro-
vided critical insights intoM. tuberculosis population dynamics, includingM. tuberculosis
transmission and the molecular causes of drug resistance [20–23]. Although some strains from
KwaZulu-Natal have been sequenced [24,25], there has been no large-scale sequencing project
from this province or studies that have systematically addressed the molecular evolution of
XDR. In the largest compilation of whole genome sequences from clinical isolates ofM. tuber-
culosis from South Africa, we used a combination of comparative genomic techniques to eluci-
date when and how epidemic XDR drug resistance emerged. With knowledge of a strain’s date
of collection, determination of the number of single nucleotide polymorphism (SNP) differ-
ences between sequenced strains, and the estimated mutation rate ofM. tuberculosis, we were
able to utilize Bayesian [26] inference to estimate the dates of acquisition of resistance
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mutations within the Tugela Ferry ancestor. We discuss the implications of these findings with
respect to current and future TB control.
Methods
Specimen Collection and Characterization
We selected 337 clinical isolates ofM. tuberculosis with diverse drug susceptibility patterns.
Strains were collected both retrospectively and prospectively from 2008 to 2013 from all 11 dis-
tricts of KwaZulu-Natal (Table 1). Strains were chosen for study inclusion on the basis of a pre-
determined drug resistance pattern so that the dataset was heavily weighted toward drug-
resistant strains rather than accurately reflecting the epidemiology of the region. Written
informed consent was obtained from study participants prior to cohort enrollment. Biomedical
Research Ethics Council (BREC) approval from the University of KwaZulu-Natal was granted
for whole genome sequencing of clinical strains. On all study isolates, drug susceptibility testing
(DST) was performed by the critical concentration method, using the WHO recommended
concentrations [27]. The following drugs were assayed in all strains, with their respective criti-
cal concentration in parentheses (in μg/mL): rifampicin (1.0), isoniazid (0.2 and/or 1.0), strep-
tomycin (2.0), kanamycin (6.0), and ofloxacin (2.0). Extended DST was performed for key
isolates (Table 1) with the following drugs: capreomycin (10.0), ethambutol (7.5), and ethion-
amide (10.0). Pyrazinamide resistance testing was performed using PZA MGIT (100.0) or Nic-
otinamide (500.0). Subject data included age, gender, AFB smear, and HIV status, when
available. Study participants were assigned GPS coordinates corresponding to their home pro-
vincial district or site of sputum collection.
We also selected for sequencing three historical strains previously collected in KwaZulu-
Natal for resequencing [25,24]: KZN4207 (drug susceptible, collected in Durban in 1995),
Table 1. Description of study isolates. The 337 clinical study isolates derived from five patient cohorts and were both prospectively and retrospectively col-
lected from all 11 districts of KwaZulu-Natal from 2008 to 2013. Culture conditions describe the initialM. tuberculosis isolation method from sputum. If subse-
quent single colony isolation (SCI) was performed prior to DNA extraction on the entire study cohort or a subset of the cohort, then this is denoted. Drugs for
which DST was performed are abbreviated as follows: rifampicin (R), isoniazid (H), nicotinamide (N), pyrazinamide (P), ethambutol (E), streptomycin (S),
kanamycin (K), ofloxacin (O), ethionamide (Et), and capreomycin (C).
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SCI entire
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Collection of Urine Blood
Sputum Study (CUBS)
Prospective collection of patients newly
initiating MDR or XDR therapy at the
central TB hospital in KwaZulu-Natal (King
DinuZulu Hospital)
Prospective, 2013 30 7H10; SCI
subset
R, H, E, S, K, O
doi:10.1371/journal.pmed.1001880.t001
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KZN1435 (MDR, collected in Durban in 1994), and KZN605 (XDR, collected in Tugela Ferry
in 2005).
Whole Genome Sequencing
Genomic DNA was extracted using published methods [31]. The majority of strains were single
colony selected prior to DNA isolation (S1 Methods and S1 Table). Library preparation and
whole genome sequencing (WGS) were performed as previously described on the Illumina
HiSeq 2000 at the Broad Institute [32]. The median depth of sequencing was 143x, and coverage
of the H37Rv genome was 99.9%. Sequencing data were submitted to the Sequence Read Archive
NCBI under the following umbrella BioProject identifiers: PRJNA183624 and PRJNA235615.
Bioinformatic Analysis
Primary analysis. Reads were mapped onto a reference strain of H37Rv (GenBank acces-
sion number CP003248.2) using BWA version 0.5.9 [33]. In cases in which read coverage of
the reference was greater than 200x, reads were down-sampled using Picard [34] prior to map-
ping. Positions that varied relative to the reference were identified using Pilon version 1.5 as
described [32].
Strain diversity and biogeography. We conducted phylogenetic analyses for both the
entire set of 340 strains, as well as for a subset of 111 strains belonging to the LAM4 spoligo-
type. For each set, all sites with unambiguous SNPs in at least one strain were combined into a
concatenated alignment. Ambiguous positions were treated as missing data. The concatenated
alignment was then used to generate a midpoint rooted phylogenetic tree in RAxML (version
7.3.3) [35] under a GTRCAT substitution model with 1,000 bootstrap replicates. GlobalM.
tuberculosis lineage designations were assigned based on phylogeny and regions of difference
[36]. Each strain’s “digital” spoligotype was predicted by statistically testing for the presence of
each of 43 unique spacer sequences used in classical spoligotyping from sequence reads. Results
were matched to spacer pattern profiles at SITVITWEB to generate a named spoligotype (S1
Methods) [37]. Clonal strains were identified using a density-based clustering algorithm [38]
that grouped strains that differ by no more than ten SNPs to at least one other member within
a clone (S1 Methods) [39–41].
Mantel tests were performed to evaluate the relationship between genetic and geographic
distances among strains using the ZT software v1.1 [42]. Pairwise genetic distances were calcu-
lated as the number of SNP differences between strains, and geographic distances were calcu-
lated using the haversine formula [43] and points of origin for strain pairs.
Ordering and dating evolution of drug resistance. A curated list of genomic polymor-
phisms associated with drug resistance was defined for each tested drug based on a literature
review (S1 Methods). Polymorphisms associated with compensatory mechanisms to isoniazid,
rifampicin, and ethambutol were also defined (S1 Methods). Strains with predicted resistance
were identified based on the carriage of mutations from the curated list. We used PAUP [44] to
reconstruct the patterns of drug resistance mutation gains and losses throughout the phyloge-
netic tree representing all 340 strains. PAUP was run using a cost matrix that assigned a 10x
greater cost for a loss event relative to a gain event. We used BEAST [26] to estimate a mutation
rate and to determine dates for the acquisition of mutations within the LAM4 spoligotype.
BEAST was run for 50 million iterations, sampling every 1,000 iterations, using the relaxed
lognormal clock (uncorrelated) model. The relaxed molecular clock model assumes indepen-
dent rates on different branches, which was consistent with previously published reports [45],
as well as initial BEAST analyses that we conducted involving lineages 2 and 4, indicating that
there may be substantial variation in evolutionary rates withinM. tuberculosis. In addition,
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since the BEAST statistic “ucld.stdev” was greater than zero (0.189) for our dataset, this indi-
cated that our data did exhibit rate heterogeneity within the LAM4 spoligotype. The first 5 mil-
lion iterations were excluded as “burn-in.”We used the GTR + Gamma substitution model,
estimated base frequencies, and the “Gamma + invariant sites” site heterogeneity model. We
enforced the topology of the SNP-based tree determined using RAxML [35]. We used a starting
value for the mean mutation rate of 0.35 SNPs/genome/year [39,41,46–48]. We assayed a range
of values for the starting mean mutation rate, covering the range of values previously reported
in the literature, with little difference in the output. BEAti was used to construct the BEAST
input file, and default values were used for all other priors. The program Tracer was used to
examine mixing and effective sample size (ESS) in order to assess chain length and model con-
vergence. ESS indicates the number of effectively independent draws from the posterior distri-
bution to which the Markov chain is equivalent. A low ESS for a particular parameter
(ESS< 100) would indicate that the trace contained a lot of correlated samples and thus may
not well represent the posterior distribution. In our analysis, all statistics had an ESS greater
than 150. The results were consistent across several runs of the same model. Estimated dates
are given with 95% highest posterior density (HPD) intervals.
Results
Our study included 337 participants with an average age of 33.8 y and a standard deviation of
10.7 y, of whom 165 (49%) were male (Table 2). Overall, 140 patients were HIV positive, 51
were HIV negative, and 146 had unknown HIV status. Baseline characteristics were similar
among HIV-positive and HIV-negative individuals, with the exception that HIV-negative indi-
viduals were younger (p = 0.0030), more likely to be smear positive (p = 0.0139), and more
likely to live outside of eThekwini, the provincial capital (p = 0.0132).
Table 2. Demographic characteristics of participants and phenotypic drug susceptibility of strains. Data are n (%) or mean ± standard deviation
(SD).
HIV Positive HIV Negative HIV Unknown All Patients
Characteristic (N = 140) (N = 51) p-value* (N = 146) (N = 337)
Age (y); mean ± SD 34.0 ± 8.5 31.8 ± 13.4 0.0030 34.3 ± 11.5 33.8 ± 10.7
Male 65 (46) 30 (59) 0.1435 70 (48) 165 (49)
Smear status
smear positive 89 (64) 42 (82) 0.0139 51 (35) 182 (54)
smear negative 50 (36) 9 (18) 0.0209 24 (16) 83 (25)
smear unknown 1 (1) 0 (0) 1.0000 71 (49) 72 (21)
Phenotypic DST results
Susceptible 39 (28) 22 (43) 0.0542 27 (18) 88 (26)
Monodrug resistant 7 (5) 2 (4) 1.0000 14 (10) 23 (7)
Polydrug resistant 4 (3) 0 (0) 0.5751 15 (10) 19 (6)
MDR sensu stricto 54 (39) 16 (31) 0.3996 70 (48) 140 (42)
XDR 36 (26) 11 (22) 0.7044 20 (14) 67 (20)
Tugela Ferry XDR† 27 (75) 8 (73) 0.6750 14 (70) 49 (73)
other XDR† 9 (25) 3 (27) 1.0000 6 (30) 18 (27)
Geography
eThekwini 73 (52) 36 (71) 0.0312 69 (47) 178 (53)
* HIV-positive and HIV-negative individuals were compared using Fisher’s exact test for categorical variables and nonparametric Mann-Whitney test for
continuous variables.
† Data in this row are from the XDR data, not the total dataset.
Results having a p-value < 0.05 were considered statistically significant.
doi:10.1371/journal.pmed.1001880.t002
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A clinical sample was obtained from each patient;M. tuberculosis was isolated using stan-
dard approaches and phenotypic DST was performed on each isolate using standard methodol-
ogy (S1 Methods). Phenotypic DST revealed 88 susceptible, 23 monodrug-resistant (defined as
phenotypic resistance to only one drug), 19 polydrug-resistant (defined as phenotypic resis-
tance to two drugs that does not meet criteria for MDR), 140 MDR sensu stricto, and 67 XDR
M. tuberculosis strains (Table 2). Phenotypic MDR and XDR-TB cases were identified in all 11
districts of KwaZulu-Natal. While we observed a trend toward HIV-negative individuals har-
boring more drug-susceptible TB, this observation did not meet statistical significance
(p = 0.0542).
We performed WGS on all 337 clinical strains, as well as on three historical strains isolated
prior to the study collection period. We assessed the diversity and phylogenetic relatedness
among strains using information from 17,232 variable sites with SNPs relative to the H37Rv
reference genome (Fig 1; S1 Fig). The resulting phylogenetic tree revealed four of the seven
main global lineages ofM. tuberculosis [36,49–51] to be circulating in KwaZulu-Natal during
the sampling time frame. The vast majority of isolates (95%) belonged to lineages 2 and 4, with
lesser representation from lineages 1 and 3.
A computational or digital spoligotype prediction was performed, and 17 unique spoligo-
types were identified (S1 Table) [37]. Spoligotype diversity was well represented in all districts
of KwaZulu-Natal (Fig 2, panel A). Using a Mantel test, we determined that there was very low
correlation between geographic and genetic distances among strains (r = -0.067906,
p = 0.001760), indicating that strains did not cluster geographically. Older transmission events
and/or high patient mobility between districts likely account for this pattern.
We defined a “clone” as a set of strains in which each member differs by no more than ten
SNPs to at least one other member, which is similar to definitions used in previous genomic
Fig 1. Diverse strains contribute to drug resistance in KwaZulu-Natal. (A) Midpoint rooted maximum-likelihood phylogeny of 340M. tuberculosis
isolates. Four of the seven knownM. tuberculosis lineages were identified: CAS (Lin1), Beijing (Lin2), EAI (Lin 3), and Euro-American (Lin4). Digital
spoligotyping identified 17 unique spoligotypes in the dataset; spoligotypes are shown on this figure if they are represented by three or more strains.
Corresponding spoligotypes and phenotypes are reported for all strains in S4 Table. Phenotypic XDR, MDR, poly- and monodrug resistance (labeled “Drug-
resistant other”), and pansusceptible strains are indicated by colored tick marks at the tip of each leaf node. (B) Histogram of pairwise SNP distances
between strains. The number of pairs within each SNP distance range is plotted. The peaks correspond to the distance between major lineages. The peak at
the far left of the figure corresponds to the distance between pairs of strains within a clone.
doi:10.1371/journal.pmed.1001880.g001
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studies ofM. tuberculosis transmission (S2 Fig, S1 Methods) [39–41]. Nearly one-third of the
strains (107 of 340, 31%) belonged to 11 such clones (S2 Table), which were distributed across
six spoligotypes and three lineages (S3 Fig). All clones were phenotypically drug resistant, indi-
cating recent person-to-person spread of a diverse set of drug-resistant strains that included
both HIV-positive and HIV-negative individuals.
The “historical” Tugela Ferry XDR strain, KZN605, was nested phylogenetically within a
large clone of 50 LAM4 strains with predominantly phenotypic XDR (Fig 3). All of the strains
within this clone (henceforth referred to as the Tugela Ferry XDR Clone) possessed the charac-
teristic drug resistance mutations that were previously identified in XDR-TB strains circulating
in Tugela Ferry during the outbreak [9,24], further indicating this clone’s continued prevalence
within KwaZulu-Natal. Patients in whom the Tugela Ferry XDR Clone was isolated were from
ten of the 11 districts within the province (Fig 2, panel B). In addition, the Tugela Ferry XDR
Clone was not overrepresented among HIV-positive patients (p = 0.6750) (Table 2). This sug-
gests that strains within this clone were neither geographically constrained nor restricted to
immunodeficient hosts.
Many of the sequenced LAM4 strains were closely related to the Tugela Ferry XDR Clone
but had different DST profiles (Fig 3 and S2 Fig), giving us an opportunity to finely dissect the
order of acquisition of mutations giving rise to the Tugela Ferry XDR Clone [9,24]. LAM4
strain phylogeny was recalculated using data from only LAM4 strains, and parsimony was used
Fig 2. Wide geographic spread of diverse strains across KwaZulu-Natal and wide distribution of XDR and the Tugela Ferry XDR Clonemembers. A
map of the 11 districts of KwaZulu-Natal [52] is shown in which pie charts indicate (A) the fraction of sequencedM. tuberculosis belonging to computationally
predicted spoligotypes (see key). In (B), the fraction of strains with a phenotypic classification of XDR and membership in the Tugela Ferry XDR Clone are
represented (see key). The size of the pie chart indicates the relative number of strains sequenced from each of the 11 districts within KwaZulu Natal. Tugela
Ferry, in the uMzinyathi district, is indicated in red.
doi:10.1371/journal.pmed.1001880.g002
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Fig 3. Molecular evolution and dating of drug resistance emergence within the Tugela Ferry XDR Clone.Midpoint rooted maximum-likelihood
phylogeny of 107M. tuberculosis isolates of the LAM4 spoligotype. The gray shaded box identifies the Tugela Ferry XDR Clone. KZN605, the historical XDR
strain collected in Tugela Ferry during the outbreak, is a member of this clone. Two additional historical isolates, KZN1435 and KZN4207, are not members of
the Tugela Ferry XDR Clone. Each evolutionary gain of a drug resistance mutation was assigned to its position on the phylogenetic tree by parsimony
(colored circles). A–E traces the stepwise order of drug resistance acquisition in the Tugela Ferry XDR Clone and estimates the year when each mutation
was gained. Gray bars indicate the 95% highest posterior density (HPD) intervals. (A) katG S315T (isoniazid); gidB 130 bp deletion (streptomycin); 1957
(95%HPD: 1937–1971); (B) inhA promoter -8 (isoniazid and ethionamide); 1964 (95% HPD: 1948–1976); (C) embBM306V (ethambutol); 1967 (95%HPD:
1950–1978); (D) rpoB L452P (rifampicin); pncA 1bp insertion (pyrazinamide); 1984 (95%HPD: 1974–1992); and (E) rpoB D435G (rifampicin); rrs 1400
(kanamycin); gyrA A90V (ofloxacin); 1995 (95%HPD: 1988–1999). The accumulation of individual drug-resistant mutations within a strain is denoted to the
right of the phylogenetic tree. The dates of drug discovery are displayed at the bottom of the figure [53]. Four additional LAM4 strains on a distant branch were
not included in this figure because of size constraints. Bootstrap values are provided for lettered nodes, and bootstrap values for all nodes are shown in S5
Fig.
doi:10.1371/journal.pmed.1001880.g003
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to place the origin of known resistance-conferring mutations on the tree. The recalculated
LAM4 tree was consistent with our previous tree containing data from all strains with all key
internal nodes involved in the evolution of drug resistance having bootstrap values greater
than 89%. This enabled us to confidently assign evolutionary ordering of drug resistance muta-
tion acquisition (Fig 3 and S5 Fig).
As shown in Fig 3, the first step towards XDR-level resistance in this epidemic clone was the
acquisition of isoniazid and streptomycin resistance-conferring mutations in katG and gidB,
respectively, which were gained at node A of the phylogenetic tree (100% bootstrap support).
With accumulation of successive mutations, the ancestral strain (and its descendants) gained
(i) additional polydrug resistance to ethionamide and ethambutol via mutations in the inhA
promoter and embB (nodes B and C, respectively, 100% and 89% bootstrap support), (ii) MDR
via mutations in rpoB and pncA that conferred resistance to rifampicin and pyrazinamide
(node D, 100% bootstrap support), and (iii) XDR via mutations in rrs and gyrA, which con-
ferred resistance to kanamycin and ofloxacin, respectively, and an additional rpoBmutation
(node E, 97% bootstrap support). This ordering was highly supported by bootstrapping (all key
nodes had bootstrap values89%) in the phylogenetic reconstruction. Thus, the first step
towards XDR-level drug resistance in this epidemic clone was the acquisition of isoniazid and
streptomycin resistance followed by ethambutol and ethionamide resistance, then rifampicin
and pyrazinamide resistance, and, ultimately, kanamycin and ofloxacin resistance.
Because we had dates of isolation for all sequenced strains—including strains that were iso-
lated more than 20 y ago—we applied a Bayesian statistical approach to estimate when muta-
tions leading to the Tugela Ferry XDR Clone emerged. Using this approach, which takes into
account the phylogeny of LAM4 strains, the dates of their isolation, and published mutation
rates forM. tuberculosis [39,41,46–48], we calculated that LAM4 in KZN mutated at a rate of
0.61 SNPs/genome/year. This mutation rate was higher than other previously published muta-
tion rates, regardless of which rate from the literature was used as the starting mean value.
Applying this rate, we estimated that drug resistance mutations at node A were acquired in
1957 (95% HPD: 1937–1971), soon after streptomycin and isoniazid were developed. MDR-
level resistance was acquired in 1984 (95% HPD: 1974–1992; node D), and XDR-level resis-
tance was acquired in 1995 (95% HPD: 1988–1999; node E), 10 y prior to its acute recognition
in 2005 in Tugela Ferry (Fig 3). The dating analysis within the LAM4 spoligotype consistently
assigned drug resistance gains after the drug discovery date, indicating that drug resistance
emergence in the region mirrored the dates of drug discovery.
We also observed multiple drug resistance mutations within LAM4 that emerged outside
the Tugela Ferry XDR Clone (Fig 3). Many of these mutations were acquired at leaf nodes,
which implied very recent gains of resistance. Including the Tugela Ferry ancestor, we calcu-
lated that genotypic MDR sensu stricto—defined as both isoniazid and rifampicin resistance-
conferring mutations—independently arose a minimum of 13 times. Within LAM4, the Tugela
Ferry XDR Clone represented the single and only evolutionary gain of genotypic XDR—as
defined by acquisition of resistance-conferring mutations to the four XDR-defining drugs: iso-
niazid, rifampicin, ofloxacin, and kanamycin. However, within LAM4 we also observed ten
independent gains of either a kanamycin or an ofloxacin resistance-conferring mutation in a
background of genotypic MDR sensu stricto. As such, 13 LAM4 strains identified in this study
would be considered genotypic “pre-XDR” and only one SNP away from XDR-level resistance.
Beyond LAM4, we observed many other independent evolutionary emergences of MDR
and XDR across this dataset. Twelve and seven spoligotypes contained strains with phenotypic
MDR and XDR, respectively (S3 Table), suggesting that these resistance patterns emerged no
fewer than 12 and 7 times. However, when we quantified the total number of independent evo-
lutionary emergences of genotypic MDR and XDR across our entire dataset, we estimated that
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MDR sensu stricto and XDR evolved no less than 56 and nine independent times, respectively
(S3 Table).
Remarkably, the first drug resistance acquisition in the Tugela Ferry XDR Clone was consis-
tent with other emergences of MDR and XDR across the entire dataset. For the 214 strains
with genotypic resistance to two or more of the MDR and XDR defining drugs, we quantified
the number of evolutions in which a specific drug resistance mutation was gained before a sec-
ond resistance mutation. We observed that isoniazid resistance via nonsynonymous mutation
at the katG S315 codon was gained before rifampicin resistance in 46 unique evolutionary
events, whereas rifampicin resistance was never acquired before the katG S315 mutation (Fig
4). When we repeated this for all pairwise comparisons, we found that isoniazid resistance,
conferred by mutation of the katG S315 codon, preceded or co-occurred with resistance muta-
tions to all other drugs in our dataset. Mutations other than the katG S315 mutations that con-
fer isoniazid resistance (i.e., inhA promoter mutations or katG deletions) occurred before
rifampicin resistance mutations in nine unique events, whereas we only observed the reverse
ordering twice. These data indicate that, beyond the Tugela Ferry XDR Clone, isoniazid resis-
tance, and in particular the S315 codon mutation in katG, has been the initial resistance-con-
ferring mutation leading to polydrug resistance, including MDR and XDR, among strains from
KwaZulu-Natal.
As in other organisms, in vitro studies have suggested that drug resistance inM. tuberculosis
may be associated with a variable fitness cost that can be offset by compensatory evolution
[18,15]. Nonsynonymous mutations in the α and β’ subunits of RNA polymerase have been pos-
tulated to compensate for fitness costs associated with rifampicin resistance [15,19]. Among our
226 strains with phenotypic rifampicin resistance, 76 strains had mutations known to compen-
sate for rifampicin resistance (S4 Table) [20,19,54,55]. Using the phylogenetic framework and
parsimony, we determined that 23 of the 27 previously described compensatory mutations had
an evolutionary pattern consistent with rifampicin compensation, i.e., mutations that evolved
only after or concurrent with mutations that conferred rifampicin resistance.
We also attempted to identify novel rifampicin compensatory mutations with this approach.
In addition to the 27 previously described mutations, we detected an additional 38
Fig 4. Isoniazid resistance is the first step towards drug resistance. Acquisition of katG S315 mutations precedes all other resistance mutations,
including rifampicin, in all instances in which the order of acquisition can be disambiguated. For the 214 strains with genotypic resistance to two or more MDR
or XDR defining drugs, and in which the order of acquisition of these mutations could be disambiguated, we quantified the number of evolutions in which
resistance to one drug was gained before resistance to a second drug. Isoniazid resistance was divided into mutations conferred by the katGS315 codon
versus “Other INH”mutations (defined as loss-of-function mutations in katG that do not involve codon 315 or mutations in the inhA promoter). Reported
numbers represent the number of independent evolutionary events (not the number of strains) in which the drug resistance indicated by the row labeled “first
resistance” was acquired before the drug resistance indicated by the column labeled “second resistance.” The background color is shaded to indicate the
fraction of unambiguous evolutionary events in which the “first resistance” was acquired before the “second resistance” for that given drug pair.
doi:10.1371/journal.pmed.1001880.g004
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nonsynonymous polymorphisms in rpoA, rpoC, and the non-rifampicin resistance-determin-
ing regions (RRDR) regions of rpoB (S4 Table). By parsimony analysis, we established the
acquisition order of these rpoA, rpoC, and non-RRDR rpoBmutations in relation to genotypic
rifampicin resistance. An additional 26 of these previously uncharacterized mutations also
evolved in a pattern consistent with a role in compensation, which suggests that they may also
function in this capacity. While there were ten unique RRDR mutations with subsequent or
concurrent evolutionary gain of a putative rifampicin compensatory polymorphism, the vast
majority of putative compensatory mutations occurred in association with rpoB S450L (p<
0.001) (S5 Table). This pattern was observed regardless of whether the compensatory mutation
was previously known or uncharacterized.
Beyond rifampicin compensation, we also applied our combined phylogenetic and parsi-
mony approach to known isoniazid and ethambutol compensatory mutations. With respect to
isoniazid compensation, only a single evolution of the ahpC promoter mutation was observed
in our dataset (S6 Table). It was gained after genotypic isoniazid resistance, which supports its
compensatory role for certain isoniazid resistance mechanisms [41]. Nonsynonymous muta-
tions in ubiA (Rv3086c) have previously been implicated in ethambutol resistance [56]. In our
dataset, there were at least two occasions in which these mutations unambiguously arose prior
to the acquisition of genotypic ethambutol resistance, suggesting that these are more likely to
be stepping-stone mutations rather than compensatory (S6 Table).
Discussion
We report on the WGS and comparative analysis of the largest collection of drug-resistantM.
tuberculosis sequenced to date from South Africa. From analysis of these genomes, we deter-
mined the molecular antecedents of the Tugela Ferry XDR Clone and dated the emergence of
genotypic resistance to eight drugs. We showed that the development of XDR in KwaZulu-
Natal had its roots in first-line drug resistance that arose in the late 1950s and MDR that
emerged in the 1980s. Our dating analysis indicated that the Tugela Ferry XDR Clone took
nearly four decades to evolve from its initial isoniazid and streptomycin resistances to full-
blown XDR. Although our data confirmed that the XDR outbreak in KwaZulu-Natal was
indeed a clonal event, we showed that drug resistance in this region is driven by both the devel-
opment of de novo drug resistance and clonal spread. We elucidated common evolutionary
patterns of drug resistance acquisition and determined that isoniazid was overwhelmingly the
first drug resistance to be acquired. Lastly, we validated that certain previously described rifam-
picin compensatory mutations do indeed evolve in a pattern consistent with compensation and
have identified 26 novel polymorphisms that may also function in this capacity. Collectively,
these data have important implications for the public health control of TB in sub-Saharan
Africa and elsewhere.
Using a combination of likelihood, parsimony, and Bayesian computational approaches, we
observed a decades-long evolutionary trajectory toward XDR-level drug resistance in LAM4
that mirrored the order and timing of introduction of antitubercular drugs into clinical practice
[57]. Though parsimony-based approaches can interpret rapid independent evolution of an
identical polymorphism in multiple strains as a single evolutionary event (occurring at a single
node), our predictions indicated that resistance-conferring mutations evolved only after each
drug’s clinical introduction and not before, as might be expected if homoplasy were a major
contributor to pattern predictions (Fig 3). In addition, one of the oldest acquired mutations
toward XDR-level resistance was a specific 130 bp deletion in gidB, which is extremely unlikely
to arise many times independently and supports accurate reconstruction in our evolutionary
analysis. Furthermore, though our calculated mutation rate for LAM4 was slightly higher than
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previous reports [39,41,46–48], our estimate was within the reported 95% HPD interval and
was based on a larger fraction of the H37Rv genome than previous studies (99.9% versus
<90% H37Rv mapping coverage) [39]. This was due to the inclusion of sequence data gener-
ated from both PCR-free short fragment and jumping libraries and analysis with improved bio-
informatics tools that enabled us to examine SNPs within more variable and high guanine-
cytosine (GC) content regions of the genome, including proline-glutamic acid (PE) and pro-
line-proline-glutamic acid (PPE) genes that have been reported to have a higher mutation rate
[58]. Thus, because we are including data from more of the genome, our estimation of theM.
tuberculosismutation rate may more closely approximate the actual mutation rate of the organ-
ism as compared to previously published studies.
Importantly, from the pattern of drug resistance evolution within LAM4, it is clear that the
precursors to XDR evolved well before the explosive South African HIV epidemic of the 1990s,
indicating that the selection of transmissible XDR strains can occur in low-prevalence HIV set-
tings. While recent failures in TB and infection control and the current high HIV prevalence
rates, combined, undoubtedly contributed to the spread of XDR, they were not the sole causes
of XDR in this setting. Indeed, strains that evolved first-line drug resistance soon after the
introduction of chemotherapy were a critical entry point to today’s drug-resistant epidemic.
Drug-resistant strains that emerged from the mid-20th century were evidently maintained
within the population ofM. tuberculosis, presenting the opportunity for the acquisition of suc-
cessive resistance and compensatory mutations that culminated in transmissible XDR and the
Tugela Ferry outbreak. Drug-resistant strains may have been maintained within a population
over time either by ongoing cycles of infection and transmission or through reactivation of
latent disease. It is unclear which of these may have been the most important in this setting,
but it suggests that fitness costs due to first-line drug resistance may not be severe. Reactivation
was recently shown to be important in the transcontinental spread of MDR-TB from Thailand
to California over a 22-y period [59], but it is unclear whether this factor was also critical in
KwaZulu-Natal.
Beyond LAM4, and as has been shown in other studies [10,14], drug resistance emerged de
novo repeatedly in KwaZulu-Natal, as evidenced by our identification of numerous indepen-
dent evolutionary events of MDR and XDR across multiple lineages and spoligotypes. Of par-
ticular note was the detection of multiple independent evolutions of MDR to pre-XDR within
LAM4, which may herald a new wave of XDR in the near future. Thus, the repeated emergence
of de novo high-level drug resistance underscores the reality that, even in middle-income sub-
Saharan African countries, the current approach to TB control is failing to stem the ongoing
emergence of drug resistance. In fact, results from our analyses suggest this was not due to
infrequent poor adherence to TB drugs but instead to decades of inadequate TB control that
has driven resistance development in a stepwise fashion, multiple times over. Given that our
estimates of resistance evolution were based on identification of known resistance-conferring
mutations and that the majority of sequenced strains were single colony purified, our calcula-
tions are likely an underestimation due to incomplete understanding of all mutations that con-
fer drug resistance and the possibility of mixed infections, respectively. Thus, the state of drug
resistance emergence is likely more dire than we have described.
Recent studies from KwaZulu-Natal have emphasized transmission of a limited number of
strains as a driving force behind the emergence of drug resistance [10,14]. Our data also con-
firm that once drug resistance develops, clonal spread of resistant strains can and does occur in
this context. We found that recent person-to-person spread of resistant strains is apparent in
KwaZulu-Natal, as evidenced by identification of multiple drug-resistant clones. Importantly,
in contrast to initial reports from Tugela Ferry in which nearly all XDR cases were TB/HIV
coinfected [7,9], eight patients in our study in whom the Tugela Ferry XDR Clone was
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identified were HIV negative. This reemphasizes that even XDR drug-resistant strains are suffi-
ciently fit to transmit person to person and cause morbidity in both immunocompetent and
immunosuppressed persons. Improved infection control and rapid case finding will be neces-
sary to prevent further spread of drug-resistant strains and to detect such cases in the commu-
nity as well as in hospital settings [28].
Our genomic analysis uncovered a common initial pattern of drug resistance that is not
optimally detected by current diagnostic algorithms. Isoniazid resistance was overwhelmingly
the first drug resistance to occur along the pathway to multiple drug resistances. However, cur-
rent TB control strategies in South Africa focus on early detection of rifampicin resistance as a
surrogate marker of MDR and do not include the detection of isoniazid resistance. Clinical
diagnostic policies that rely on Xpert MTB/RIF (a WHO-endorsed and widely deployed molec-
ular diagnostic) [60] without more extensive drug resistance testing allow isoniazid resistance
to go undetected and unchecked. Moreover, under current short course treatment guidelines
that utilize 4 mo of isoniazid and rifampicin in the continuation phase [61], failure to recognize
isoniazid monoresistance is tantamount to provision of unopposed rifampicin therapy and
may rapidly select for rifampicin resistance. This phenomenon may be underappreciated and
incompletely accounted for in mathematical models that recommend continued use of screen-
ing tools that identify only rifampicin resistance [62]. Furthermore, if rifampicin resistance is
indeed detected by Xpert, failure to implement confirmatory secondary molecular testing for
dual rifampin and isoniazid resistance, as is mandated by South African policy, occurs at unac-
ceptably high rates [63]. Our ordering of drug resistance acquisition provides strong evidence
that isoniazid monoresistance is a common pathway toward development of MDR and high-
lights the importance of prompt identification and treatment of isoniazid monoresistance. Fail-
ure to do so would be recapitulating the scenario that led to the current XDR problem.
Beyond detection, identification of the initial drivers of isoniazid monoresistance is also crit-
ical to the prevention of successive resistances. Isoniazid preventive therapy (IPT) has previ-
ously been implicated as a potential source of isoniazid monoresistance [64,65]. Our work
highlights the need to understand the true risks of mass IPT implementation [66] in high-bur-
den settings.
We were able to verify that the evolutionary patterns of select previously described rifampicin
and isoniazid compensatory mutations do indeed appear to be consistent with compensation to
their respective drug. Similarly, ubiA was observed to evolve in a stepping-stone pattern rather
than a compensatory pattern with respect to ethambutol resistance [56]. Furthermore, we have
identified novel putative rifampicin compensatory mutations that may have acted to restore bac-
terial fitness and facilitate transmission of drug-resistant strains. While the majority of the previ-
ously described rifampicin compensatory mutations had an evolutionary pattern consistent with
this role, four polymorphisms previously associated with rifampicin compensation (rpoB I491F,
rpoCG594E and N826K, and rpoA E319K) were not observed to evolve concurrently or subse-
quent to genotypic rifampicin resistance (S4 Table). These mutations may (i) not be compensa-
tory mutations in the classic sense (i.e., mutations that evolve following gain of genotypic drug
resistance to mitigate a fitness cost) but instead serve as stepping-stone mutations, (ii) evolve in
concert with non-RRDR genotypic rifampicin resistance, or (iii) have no association with rifam-
picin resistance. We have proposed 26 novel mutations whose evolutionary patterns are consis-
tent with rifampicin compensation, and these should be investigated in future studies.
The most commonly observed genotypic rifampicin resistance mutation among our
sequenced strains was rpoB S450L (often referred to as S531L using the Escherichia coli codon
numbering scheme), which is known to be the most prevalent RRDR mutation. Laboratory-
derived strains carrying the S450L were previously shown to have relatively high fitness in in
vitro growth assays [15], supporting the hypothesis that high prevalence of the S450L mutation
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among clinical strains was due to it imparting few fitness consequences. However, as shown in
our study and in several others [20,54], rpoB S450L was the most likely RRDR polymorphism
to evolve putative compensatory mutations, which calls into question the low fitness cost of
S450L in vivo. Song et al. assessed rifampicin fitness by transcriptional efficiency (rather than
growth) and showed that the S450L mutation has half the transcriptional efficiency of WT
rpoB [54], which is likely to impart fitness consequences if not compensated.
This study has two main limitations. First, as our study isolates derived from only one geo-
graphic region, our conclusions regarding the timing and dating of the emergence of resistance
may not be universal. However, two recent studies [67,68] have reported results compatible
with ours from different settings. Using a similar approach, Eldholm et al. were able to date the
first emergence of resistance in an MDR-TB outbreak from Argentina to the early 1970s and
found that isoniazid and streptomycin resistance-conferring mutations were the first to be
acquired. In a study of the global spread of the Beijing lineage [23], isoniazid and streptomycin
resistances were also found to be common to all drug-resistant strains in two clonal complexes
that resulted in the epidemic spread of two MDR clones in Russia and Central Asia 20 to 30 y
ago. Another limitation, as discussed above, is that parsimony-based dating approaches may
fail to distinguish rapid independent evolutions of a commonly occurring resistance mutation
as two unique evolutionary events. This could lead to erroneous assignment of a mutation to a
more basal part of the phylogenetic tree. While a theoretical risk, we believe the effect was min-
imal in our dataset since, as described above, our predictions were consistent with the timing of
drug introduction, and we included a specific large deletion that is extremely unlikely to arise
many times independently.
Here, we present the largest WGS study conducted to date of drug-resistant clinical isolates
ofM. tuberculosis from South Africa. Our dating analysis highlights the dire repercussions of
failure to control first-line drug resistance. As acquisition of isoniazid resistance is the key initia-
tion event for progression to MDR and beyond, TB control efforts that focus on the identifica-
tion of isoniazid as well as rifampicin resistance will result in earlier detection of drug-resistant
TB cases. Prudent antibiotic stewardship during the introduction of new antitubercular drugs
will be critical to prevent the early fixation of resistance and protect the lifespan of novel agents.
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Editors' Summary
Background
Tuberculosis (TB)—a contagious bacterial disease that usually infects the lungs—is a
global public health problem. Every year, about 9 million people develop active TB disease,
and 1.5 million people die from the disease.Mycobacterium tuberculosis, the organism
that causes TB, is spread in airborne droplets when people with TB cough. The symptoms
of TB include cough, weight loss, and fever. Diagnostic tests for the disease include sputum
smear microscopy (microscopic analysis of mucus coughed up from the lungs) and chest
X-rays. TB can be cured by taking a regimen of multiple antibiotics daily for 6 mo. How-
ever, the emergence of multidrug-resistant tuberculosis (MDR-TB, TB with resistance to
both isoniazid and rifampicin) and extensively drug-resistant tuberculosis (XDR-TB,
MDR-TB with additional resistance to both quinolones and second-line injectable agents),
together with the spread of HIV (which increases susceptibility to TB), is now threatening
TB control efforts. MDR-TB is caused byM. tuberculosis strains that have acquired muta-
tions (genetic changes) that make them resistant to isoniazid, rifampicin, and sometimes
other anti-TB drugs; XDR-TB is caused by bacteria that are resistant to isoniazid, rifampi-
cin, one or more fluoroquinolones (for example, ofloxacin), and at least one injectable sec-
ond-line drug (for example, kanamycin).
WhyWas This Study Done?
A better understanding of the origins of drug-resistant TB is essential for effective control
of TB. Public health experts need to know whether the emergence of drug-resistant TB is
caused by inadequacies in TB control or related to other factors such as the spread of HIV
and whether new resistant strains ofM. tuberculosis repeatedly emerge during XDR-TB
outbreaks or whether the transmission of a single drug-resistant strain drives these out-
breaks. Here, the researchers use whole genome sequencing and dating analysis to investi-
gate the origin and evolution of an XDR-TB outbreak identified in 2005 in Tugela Ferry,
KwaZulu-Natal, South Africa. The predominant strain of XDRM. tuberculosis isolated
during this large XDR-TB outbreak belongs to a subfamily called LAM4. Since the out-
break began, XDR-TB has also been reported in hospitals across KwaZulu-Natal, and
some of these outbreaks have been caused by bacterial strains not falling within the LAM4
spoligotype (“spoligotyping” characterizesM. tuberculosis strains based on the presence of
unique DNA sequences in a specific region of the bacterial genome).
What Did the Researchers Do and Find?
The researchers tested the antibiotic susceptibility of 337 clinical isolates ofM. tuberculosis
collected in KwaZulu-Natal between 2008 and 2013 and of three historical isolates—two
collected in the province in the mid-1990s and a third from the Tugela Ferry XDR out-
break. They sequenced the whole genome of these isolates and used comparative tech-
niques to assess the isolates’ relatedness and to investigate the acquisition of drug
resistance. This analysis revealed a 50-member clone of XDR bacteria among the isolates
collected across KwaZulu-Natal that was highly related to the LAM4 strain (a clone is
defined here as a set of strains in which each member differs by no more than ten single
nucleotide polymorphisms [SNPs] from at least one other member; an SNP is a type of
genetic variant). Mutations that conferred isoniazid resistance in this clone were acquired
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in about 1957; MDR and XDR strains emerged in about 1984 and 1995, respectively. The
analysis also indicates that MDR and XDR evolved de novo 56 times and nine times,
respectively, and that isoniazid resistance nearly always evolved before rifampicin
resistance.
What Do These Findings Mean?
These findings provide new information about the ordering and timing of the acquisition
of drug-resistance mutations byM. tuberculosis in KwaZulu-Natal but do not necessarily
represent the evolution of XDR-TB in other settings. Most notably, these findings indicate
that the ancestral precursor of the Tugela Ferry XDR outbreak strain gained resistance to
first-line antibiotics shortly after these antibiotics became available for clinical use. Subse-
quent stepwise accumulation of additional resistance mutations that occurred over
decades led to the emergence of MDR and XDR strains. Importantly, the emergence of
these strains occurred before the explosion of HIV in KwaZulu-Natal. Thus, these findings
highlight the dire repercussions of the failure of historic attempts to control resistance to
first-line anti-TB drugs and draw attention to the need for new anti-TB drugs to be used
prudently to prevent early fixation of resistance and to protect the useful lifespan of these
agents. Finally, the finding that isoniazid resistance is a key initiation event for progression
to MDR and XDR suggests that TB control programs should test routinely for both isonia-
zid and rifampicin resistance to ensure early detection of drug-resistant TB.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001880.
• TheWorld Health Organization (WHO) provides information (in several languages) on
TB and on MDR-TB; the Global Tuberculosis Report 2014 provides information about
TB around the world; a supplement to the report entitled “Drug-Resistant TB—
Surveillance and Response” is available
• The Stop TB Partnership is working towards TB elimination and provides personal
stories about TB (in English and Spanish)
• The United States Centers for Disease Control and Prevention provides information
about TB and about drug-resistant TB (in English and Spanish)
• The US National Institute of Allergy and Infectious Diseases also has detailed informa-
tion on TB, including a drug-resistant TB visual tour
• TB &Me, a collaborative blogging project run by patients being treated for MDR-TB
and Mèdecins sans Frontiéres, provides more patient stories
• The not-for-profit organization Global Health Education provides information about
TB in South Africa
• MedlinePlus has links to further information about TB (in English and Spanish)
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